Compare SAMG & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SAMG | CING |
|---|---|---|
| Founded | 2002 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 64.5M |
| IPO Year | 2012 | 2021 |
| Metric | SAMG | CING |
|---|---|---|
| Price | $10.02 | $4.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $34.50 |
| AVG Volume (30 Days) | 53.2K | ★ 146.4K |
| Earning Date | 05-01-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.36% | N/A |
| EPS Growth | N/A | ★ 56.47 |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $91,358,000.00 | N/A |
| Revenue This Year | $8.99 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $203.40 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.57 | $3.16 |
| 52 Week High | $16.88 | $11.89 |
| Indicator | SAMG | CING |
|---|---|---|
| Relative Strength Index (RSI) | 48.00 | N/A |
| Support Level | $9.64 | N/A |
| Resistance Level | $11.61 | N/A |
| Average True Range (ATR) | 0.37 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 43.48 | 0.00 |
Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income, and cash, as well as non-traditional investment strategies including hedge funds, private equity funds, real estate, and commodities. The firm offers a full suite of complementary and customized family office services for families seeking comprehensive oversight of their financial affairs. The company derives revenues from Managed accounts, Silvercrest funds, Tax and family office services, and Fund administration. The firm generates the majority of its revenue from Managed Accounts.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.